New CEO and Key Board of Directors Appointments Join Co-Founders and Preeminent HDAC Scientists from Dana-Farber and Harvard University to Lead Development of Highly Selective HDAC Therapeutics CAMBRIDGE, Mass., Aug 7–(HSMN NewsFeed)–Acetylon Pharmace…
Biopharmaceuticals, Venture Capital, Personnel
Acetylon Pharmaceuticals

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Acetylon Pharmaceuticals Raises $7.25 Million Series A to Develop Next-Generation Selective HDAC Inhibitors for Cancer and Rheumatoid Arthritis”
Leave a Comment